NFE2L2 and tuberous sclerosis: We propose that therapeutics inhibiting redox or iron adaptation, such as Nrf‐2 inhibitors or ferroptotic agents, might have therapeutic value to specifically target a subset of pathogenic cells in TSC and FCD IIb.